Suchergebnisse - "Perrone, Francesco"

PubPharm (46)

1

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France : a phase 3, open-label, randomised controlled trial

enthalten in: Lancet (London, England) | 2023

von Chu, Q. | Perrone, F. | Greillier, L. | +32

CommentIn: Lancet. 2023 Dec 16;402(10419):2266-2267. - PMID 37931626

2

Brief Report : Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Piccirillo, M. | Chu, Q. | Bradbury, P. | +32

CommentIn: J Thorac Oncol. 2023 Jun;18(6):e67-e68. - PMID 37210188

3

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3) : a multicentre, open-label, randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Pignata, S. | Scambia, G. | Schettino, C. | +128

CommentIn: Lancet Oncol. 2023 Mar;24(3):201-203. - PMID 37052963

4

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC : The BEVERLY Multicenter Randomized Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Piccirillo, M. | Bonanno, L. | Garassino, M. | +30

5

Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab : secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2021

von Di Liello, R. | Arenare, L. | Raspagliesi, F. | +32

6

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Cascinu, S. | Berardi, R. | Bianco, R. | +22

7

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer : a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Pignata, S. | Lorusso, D. | Joly, F. | +62

8

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer : HOBOE phase 3 randomised trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Perrone, F. | De Laurentiis, M. | De Placido, S. | +29

CommentIn: Eur J Cancer. 2019 Sep;118:166-168. - PMID 31374402

9

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

enthalten in: Gynecologic oncology | 2019

von Daniele, G. | Arenare, L. | Scambia, G. | +25

10

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer : Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Morabito, A. | Piccirillo, M. | Maione, P. | +27

1
2
3
4
5
Nächster »
[5]